
Ilaria Gandoglia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9302567/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine, 2021, 72, 103581.	6.1	184
2	Breakthrough SARS-CoV-2 infections after COVID-19 mRNA vaccination in MS patients on disease modifying therapies during the Delta and the Omicron waves in Italy. EBioMedicine, 2022, 80, 104042.	6.1	54
3	SARS-CoV-2 and Stroke Characteristics. Stroke, 2021, 52, e117-e130.	2.0	51
4	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. Neurotherapeutics, 2020, 17, 200-207.	4.4	39
5	Myasthenia gravis associated with antiâ€MuSK antibodies developed after SARSâ€CoVâ€2 infection. European Journal of Neurology, 2021, 28, 3537-3539.	3.3	39
6	Urinary JCV-DNA Testing during Natalizumab Treatment May Increase Accuracy of PML Risk Stratification. Journal of NeuroImmune Pharmacology, 2012, 7, 665-672.	4.1	29
7	Teriflunomide treatment reduces B cells in patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2017, 4, e403.	6.0	28
8	In vitro VLA-4 blockade results in an impaired NK cell-mediated immune surveillance against melanoma. Immunology Letters, 2017, 181, 109-115.	2.5	16
9	The importance of thinking about Guillain-Barré syndrome during the COVID-19 pandemic: a case with pure dysautonomic presentation. Journal of NeuroVirology, 2021, 27, 662-665.	2.1	15
10	Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. BMC Neurology, 2014, 14, 103.	1.8	10
11	Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine. Human Vaccines and Immunotherapeutics, 2014, 10, 1969-1973.	3.3	9
12	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. Journal of the Neurological Sciences, 2021, 424, 117385.	0.6	9
13	A multicentric pharmacovigilance study: collection and analysis of adverse drug reactions in relapsing-remitting multiple sclerosis patients. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1765-1788.	2.0	7
14	A peculiar case of internal carotid dissection: "do not forget Eagle's syndrome!― Neurological Sciences, 2021, 42, 2527-2529.	1.9	2
15	Response to: "MuSKâ€positive myasthenia may be triggered not only by SARSâ€CoVâ€⊋â€. European Journal Neurology, 2021, 28, e82-e83.	of 3.3	1
16	Unraveling the regulatory role of NK cells on T-cell effector functions: Implications for CNS autoimmunity. Journal of Neuroimmunology, 2014, 275, 54-55.	2.3	0
17	Do NK cells play a role in the possible association between natalizumab treatment and the development of melanoma?. Journal of Neuroimmunology, 2014, 275, 218.	2.3	0